Clinical trials: Rifampin
Pharmacokinetics of YM178
Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.
- Trial name
- NCT00776516
- Testing
- mirabegron, rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy Volunteers
Prediction of Drug Interactions With CYP2C9 Substrates
CYP2C9, is one of the major drug metabolism enzymes accounting for about 20% of the hepatic cytochrome P450 content and being second only to CYP3A4.
- Trial name
- NCT00226538
- Testing
- Phenytoin, Rifampicin, Diclophenac
- Where
- Israel
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Drug Interactions, Neoplasms
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
This is a Phase I, single center, two-part, randomized, open label, cross-over study. Part 1 of this study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following…
- Trial name
- NCT02706535
- Testing
- GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.
- Trial name
- Z650 (NCT05057949)
- Testing
- Larotinib, Rifampin, Itraconazole
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects
This is a Phase 1 open-label study of the effect of rifampin on the pharmacokinetics of CTP-543 in healthy subjects.
- Trial name
- NCT04843540
- Testing
- CTP-543
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Healthy Male Volunteers
Pharmacokinetic Drug Interaction Study in Healthy Male Subjects
A Randomized, Open Label, Drug-Drug interaction study to investigate effect of ketoconazole or rifampicin on the Pharmacokinetic characteristics and safety of LC15-0444 in Healthy Male Volunteers.
- Trial name
- NCT01426906
- Testing
- Ketoconazole, rifampicin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Pharmacokinetics
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel.
- Trial name
- NCT02820935
- Testing
- CC-220, Rifampin, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Endometriosis
Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan
This study will be conducted in a single center, open-label study with a single group fixed sequence design to evaluate the effect of repeated oral administration of 600 mg RIF(Rifampicin) given once daily over 11 days on the…
- Trial name
- NCT02975440
- Testing
- Rifampicin, Midazolam, BAY1002670_Vilaprisan
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumor
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)（n=56）
- Trial name
- NCT05357820
- Testing
- AB-106, Itraconazole, AB-106, Rifampicin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
This study evaluates how a drug that alters liver enzymes (rifampin) affects the metabolism of enzalutamide in men by measuring concentrations of enzalutamide and its metabolites in plasma.
- Conditions
- Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide
- Trial name
- NCT02138799
- Testing
- enzalutamide, rifampin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when administered with rifampin in healthy subjects
- Trial name
- DDI (NCT01947777)
- Testing
- IPI-145, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- SecuraBio
Healthy
The Safety of Tuberculosis Treatments by Oral Inhalation
The inhaled route of delivery has always been associated with the considerable challenge of getting the drug to its target. The lungs are a highly complex organ designed to filter inspired air, with many different cell types…
- Trial name
- NCT01785927
- Testing
- ABCD
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Erectile Dysfunction
Drug-Drug Interaction (DDI) Study for TPN171H
The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy male subjects ,and assess the effect of…
- Trial name
- NCT06090123
- Testing
- TPN171H, Itraconazole, Rifampicin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Cystic Fibrosis
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
The purpose of this study is to examine the drug-drug interaction effects of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor as well as to evaluate the potential…
- Trial name
- NCT01768663
- Testing
- Lumacaftor, Ivacaftor, Ciprofloxacin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Drug Interaction Potentiation
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
The present study is designed to assess the effects of Rifampin on the pharmacokinetics of N91115 in healthy subjects.
- Trial name
- NCT02500667
- Testing
- N91115, Rifampin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nivalis Therapeutics, Inc.
Gastrointestinal Hormones
Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8
The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2 on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a single-dose of the transporter inhibitor…
- Trial name
- NCT02507167
- Testing
- mixed meal, Rifampin
- Where
- Germany
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Tuberculosis
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
This is a open-label study, 2-treatment, 2-period, single sequence design. Period 1 will examine the pharmacokinetics of TMC207 in the absence of rifapentine or rifampicin.
- Trial name
- NCT02216331
- Testing
- TMC207, rifapentine, rifampicin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Healthy
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
This is a Phase 1, single center, fixed sequence, open label, drug-drug interaction study of the effect of multiple doses of rifampin 600 mg daily, a strong CYP3A inducer, on the exposure of mifepristone at 2 dose levels.
- Trial name
- NCT03258372
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
The study will consist of two open-label periods, a Treatment Period I (deferasirox) and a Treatment Period II (rifampicin+deferasirox). At least 18 subjects are expected to complete both treatment periods as per protocol.
- Trial name
- NCT00419172
- Testing
- Deferasirox, Rifampicin
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis